WO2002020090A3 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
WO2002020090A3
WO2002020090A3 PCT/EP2001/010448 EP0110448W WO0220090A3 WO 2002020090 A3 WO2002020090 A3 WO 2002020090A3 EP 0110448 W EP0110448 W EP 0110448W WO 0220090 A3 WO0220090 A3 WO 0220090A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
composition
condition
disorder
fluoroanilino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/010448
Other languages
French (fr)
Other versions
WO2002020090A2 (en
WO2002020090A9 (en
Inventor
Simon David Bateman
Alberto Gimona
Jurij Holinej
Jasper Huels
Sumedha Jayawardene
Argeris Jerry Karabelas
Maha Y Khaled
Anees Abdulquadar Karnachi
Lochlainn Eimear Mairin Nic
Richard Macerata
Victor Sloan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0301128A priority Critical patent/HUP0301128A3/en
Priority to NZ524785A priority patent/NZ524785A/en
Priority to AU1390002A priority patent/AU1390002A/en
Priority to JP2002524572A priority patent/JP2004527458A/en
Priority to IL15423801A priority patent/IL154238A0/en
Priority to SI200130773T priority patent/SI1331972T1/en
Priority to DK01982270T priority patent/DK1331972T3/en
Priority to BR0113809-0A priority patent/BR0113809A/en
Priority to KR10-2003-7002711A priority patent/KR20030036730A/en
Priority to AU2002213900A priority patent/AU2002213900C1/en
Priority to CA2416771A priority patent/CA2416771C/en
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Priority to DE60129238T priority patent/DE60129238T2/en
Priority to SK290-2003A priority patent/SK2902003A3/en
Priority to EP01982270A priority patent/EP1331972B1/en
Priority to MXPA03002105A priority patent/MXPA03002105A/en
Publication of WO2002020090A2 publication Critical patent/WO2002020090A2/en
Priority to IL154238A priority patent/IL154238A/en
Priority to NO20031095A priority patent/NO20031095L/en
Anticipated expiration legal-status Critical
Publication of WO2002020090A3 publication Critical patent/WO2002020090A3/en
Publication of WO2002020090A9 publication Critical patent/WO2002020090A9/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition for treating a cyclooxygenase-2 dependent disorder or condition comprising: 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid or a pharmaceutically acceptable salt thereof, which composition is an immediate release pharmaceutical composition for treatment of said disorder or condition for about 24 hours.
PCT/EP2001/010448 2000-09-11 2001-09-10 Pharmaceutical compositions Ceased WO2002020090A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CA2416771A CA2416771C (en) 2000-09-11 2001-09-10 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
AU1390002A AU1390002A (en) 2000-09-11 2001-09-10 Pharmaceutical compositions
JP2002524572A JP2004527458A (en) 2000-09-11 2001-09-10 Pharmaceutical composition
IL15423801A IL154238A0 (en) 2000-09-11 2001-09-10 Pharmaceutical composition
SI200130773T SI1331972T1 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions
DK01982270T DK1331972T3 (en) 2000-09-11 2001-09-10 Pharmaceuticals
DE60129238T DE60129238T2 (en) 2000-09-11 2001-09-10 PHARMACEUTICAL COMPOSITION
NZ524785A NZ524785A (en) 2000-09-11 2001-09-10 Immediate release compositions comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino) phenylacetic acid for treating cyclooxygenase-2 dependent disorders
AU2002213900A AU2002213900C1 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions
HU0301128A HUP0301128A3 (en) 2000-09-11 2001-09-10 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid containg pharmaceutical compositions for treating a cyclooxygenase-2 dependent disorder and their use
KR10-2003-7002711A KR20030036730A (en) 2000-09-11 2001-09-10 Pharmaceutical compositions
BR0113809-0A BR0113809A (en) 2000-09-11 2001-09-10 Pharmaceutical Compositions
SK290-2003A SK2902003A3 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof
EP01982270A EP1331972B1 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions
MXPA03002105A MXPA03002105A (en) 2000-09-11 2001-09-10 Pharmaceutical compositions.
IL154238A IL154238A (en) 2000-09-11 2003-01-30 Use of 5 - methyl - 2- (2' - chloro - 6' - fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cyclooxygenase - 2 dependent disorder and a medicament package comprising the same
NO20031095A NO20031095L (en) 2000-09-11 2003-03-10 Pharmaceutical compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23165500P 2000-09-11 2000-09-11
US60/231,655 2000-09-11
US23226100P 2000-09-14 2000-09-14
US60/232,261 2000-09-14

Publications (3)

Publication Number Publication Date
WO2002020090A2 WO2002020090A2 (en) 2002-03-14
WO2002020090A3 true WO2002020090A3 (en) 2003-05-30
WO2002020090A9 WO2002020090A9 (en) 2003-10-30

Family

ID=26925315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010448 Ceased WO2002020090A2 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions

Country Status (28)

Country Link
US (2) US20020061932A1 (en)
EP (1) EP1331972B1 (en)
JP (2) JP2004527458A (en)
KR (1) KR20030036730A (en)
CN (1) CN100490797C (en)
AR (1) AR030630A1 (en)
AT (1) ATE366128T1 (en)
AU (2) AU2002213900C1 (en)
BR (1) BR0113809A (en)
CA (1) CA2416771C (en)
CY (1) CY1107729T1 (en)
CZ (1) CZ2003673A3 (en)
DE (1) DE60129238T2 (en)
DK (1) DK1331972T3 (en)
ES (1) ES2290181T3 (en)
HU (1) HUP0301128A3 (en)
IL (2) IL154238A0 (en)
MX (1) MXPA03002105A (en)
MY (1) MY126117A (en)
NO (1) NO20031095L (en)
NZ (1) NZ524785A (en)
PE (1) PE20020351A1 (en)
PL (1) PL359721A1 (en)
PT (1) PT1331972E (en)
RU (1) RU2316324C2 (en)
SI (1) SI1331972T1 (en)
SK (1) SK2902003A3 (en)
WO (1) WO2002020090A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030323A1 (en) * 2001-08-31 2003-05-12 Novartis Ag PHARMACEUTICAL COMPOSITION
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
RU2318497C2 (en) * 2002-03-07 2008-03-10 Новартис Аг Pharmaceutical compositions
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AR042206A1 (en) 2002-11-26 2005-06-15 Novartis Ag PHENYLACETIC ACIDS AND DERIVATIVES
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
RU2423979C2 (en) * 2005-06-17 2011-07-20 АФТ Фармасьютикалз Лимитед Novel pharmaceutic composition and its application in method of treatment of patients with hyperaemia and edema of mucous membrane of upper airways
FR2898492B1 (en) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa ORODISPERSIBLE TABLETS OF DOMPERIDONE
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
WO2008086530A2 (en) * 2007-01-11 2008-07-17 Analog Devices, Inc. Mems sensor with cap electrode
WO2010022211A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity
WO2010056741A2 (en) 2008-11-12 2010-05-20 Auspex Pharmaceuticals, Inc. Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (en) * 2013-12-31 2016-05-18 上海复力生物医药科技有限公司 The preparation method of krill oil
WO2018049027A1 (en) 2016-09-07 2018-03-15 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and pge2 antagonists
CN111278433A (en) 2017-09-26 2020-06-12 特沙诺有限公司 Nilaparib formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011605A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ267417A (en) * 1993-06-08 1997-02-24 Ciba Geigy Ag An inclusion compound of diclofenac and gamma-cyclodextrin and compressed dosage forms thereof
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AU3004997A (en) * 1996-05-17 1997-12-09 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
SA99191255B1 (en) * 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
PE20030323A1 (en) * 2001-08-31 2003-05-12 Novartis Ag PHARMACEUTICAL COMPOSITION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011605A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives

Also Published As

Publication number Publication date
DE60129238T2 (en) 2008-03-06
ES2290181T3 (en) 2008-02-16
EP1331972B1 (en) 2007-07-04
MXPA03002105A (en) 2003-06-19
KR20030036730A (en) 2003-05-09
MY126117A (en) 2006-09-29
NO20031095D0 (en) 2003-03-10
RU2316324C2 (en) 2008-02-10
WO2002020090A2 (en) 2002-03-14
CA2416771A1 (en) 2002-03-14
EP1331972A2 (en) 2003-08-06
AU2002213900B2 (en) 2006-02-16
US20020061932A1 (en) 2002-05-23
CN100490797C (en) 2009-05-27
BR0113809A (en) 2003-07-29
CN1455691A (en) 2003-11-12
DK1331972T3 (en) 2007-11-05
AU2002213900C1 (en) 2006-07-27
ATE366128T1 (en) 2007-07-15
CY1107729T1 (en) 2013-04-18
JP2004527458A (en) 2004-09-09
AU1390002A (en) 2002-03-22
HUP0301128A2 (en) 2003-10-28
WO2002020090A9 (en) 2003-10-30
US20040186179A1 (en) 2004-09-23
CZ2003673A3 (en) 2003-06-18
DE60129238D1 (en) 2007-08-16
HUP0301128A3 (en) 2005-04-28
CA2416771C (en) 2010-11-02
PE20020351A1 (en) 2002-06-14
PT1331972E (en) 2007-10-16
NO20031095L (en) 2003-03-10
NZ524785A (en) 2005-10-28
AR030630A1 (en) 2003-08-27
SI1331972T1 (en) 2007-12-31
PL359721A1 (en) 2004-09-06
IL154238A0 (en) 2003-09-17
IL154238A (en) 2008-11-26
JP2011144194A (en) 2011-07-28
SK2902003A3 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
CY1107729T1 (en) PHARMACEUTICAL COMPOSITIONS
CA2297832A1 (en) Pellet-type formulation intended for treating the intestinal tract
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2378469A1 (en) An oral solid composition comprising carbidopa, levodopa and entacapone
HUP9802999A2 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
HK1054489A1 (en) Composition comprising free amino acids
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
DK1227806T3 (en) Pharmaceutical preparation containing tolterodine and its use
WO2004032845A3 (en) R-nsaid esters and their use
WO2002013766A3 (en) Valproic acid derivatives for the treatment of pain
WO2002058692A3 (en) Halogenated composition, method for preparing same and uses thereof
BRPI0208468B8 (en) amlodipine camsylate and process for its preparation
MXPA04001933A (en) Pharmaceutical composition comprising lumiracoxib.
DE60035429D1 (en) USE OF SULFODE HYDROABETIC ACIDS FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
WO2002005642A3 (en) Synergistic biocidal compositions
BR0311642A (en) Increased Release Sodium Divalproex Formulation
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
DK0866711T3 (en) Use of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamide for the preparation of a pharmaceutical composition for the prevention of sleep apnea
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
EP1179342A4 (en) Immediate release medicinal compositions for oral use
MY122477A (en) Sertraline oral concentrate
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
AU2002233353A1 (en) Process for the preparation of d-pantothenic acid and/or salts thereof
DE69927997D1 (en) Novel pyrimidine derivatives and method for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001982270

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2416771

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003/00555

Country of ref document: ZA

Ref document number: 200300555

Country of ref document: ZA

Ref document number: 1200300067

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 154238

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 256/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 03012650

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020037002711

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002213900

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002524572

Country of ref document: JP

Ref document number: PV2003-673

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2902003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 018154549

Country of ref document: CN

Ref document number: PA/a/2003/002105

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 524785

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2003109606

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037002711

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-673

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001982270

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 524785

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524785

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001982270

Country of ref document: EP